No Data
No Data
Phathom Pharmaceuticals Outperforms With Voquezna Driving Revenue Growth: Buy Rating Reaffirmed
Phathom Pharmaceuticals Non-GAAP EPS of -$1.25, Revenue of $7.3M
Express News | As Of June 30, 2024, Phathom Pharmaceuticals' Cash And Cash Equivalents Were $276.2M, The Company Believes It Will Have Sufficient Capital To Fund Operations Through The End Of 2026
Express News | Phathom Pharmaceuticals Q2 2024 Adj. EPS $(1.25) Beats $(1.38) Estimate, Sales $7.324M Beat $5.809M Estimate
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Express News | Phathom Pharmaceuticals Q2 Net Income USD -91.446 Million
No Data